Osteoporosis Mechanism of Disease Animation
Created for Biopharmaceutical client
Link copied!
Sclerostin, a Wnt antagonist, is produced when there is decreased load on bone and decreased estrogen during menopause. Sclerostin molecule floating in bone cellular environment. © 2016. All rights reserved.
Cross section view of osteoporotic bone structure in comparison with normal bone showing reduced thickness of both compact and spongy (trabecular) bone. Structural integrity of bone is compromised in osteoporotic bone which can result in low-impact fractures. © 2016. All rights reserved.
Trabecula in bone cellular environment with osteoblasts and osteoclasts present. The osteoblasts contribute to the formation of new bone, while osteoclasts are responsible for bone resorbtion. © 2016. All rights reserved.
3D patient render. Older woman walking down the street, trips on a crack in the sidewalk. Due to fragility in her bones from osteoporosis she endures a fracture. © 2016. All rights reserved.
The project
Created for disease state education on the molecular pathways underlying osteoporosis. Sclerostin is one of many factors that affects the downregulation of osteoblasts and overactivity of osteoclasts. The resulting imbalance can lead to fragility fractures in patients with osteoporosis.
Created for
Biopharmaceutical client
